Literature DB >> 19889117

Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient.

J A Douglass1, K Carroll, A Voskamp, P Bourke, A Wei, R E O'Hehir.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19889117     DOI： 10.1111/j.1398-9995.2009.02259.x

Source DB:  PubMed          Journal:  Allergy        ISSN： 0105-4538            Impact factor:   13.146


× No keyword cloud information.
  16 in total

Review 1.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 2.  Anaphylaxis as a clinical manifestation of clonal mast cell disorders.

Authors:  A Matito; I Alvarez-Twose; J M Morgado; L Sánchez-Muñoz; A Orfao; L Escribano
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

Review 3.  Systemic mastocytosis: a gastroenterological perspective.

Authors:  Hamish Philpott; Paul Gow; Peter Crowley; Sanjay Nandurkar; Jo Douglass; Peter R Gibson
Journal:  Frontline Gastroenterol       Date:  2011-09-10

4.  Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab.

Authors:  Matthew C Bell; Daniel J Jackson
Journal:  Ann Allergy Asthma Immunol       Date:  2012-03-21       Impact factor: 6.347

Review 5.  Target Therapies for Systemic Mastocytosis: An Update.

Authors:  Mariarita Sciumè; Claudio De Magistris; Nicole Galli; Eleonora Ferretti; Giulia Milesi; Pasquale De Roberto; Sonia Fabris; Federica Irene Grifoni
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-11

Review 6.  Mastocytosis: update on pharmacotherapy and future directions.

Authors:  Juan Carlos Cardet; Cem Akin; Min Jung Lee
Journal:  Expert Opin Pharmacother       Date:  2013-10       Impact factor: 3.889

Review 7.  Use of omalizumab in the treatment of food allergy and anaphylaxis.

Authors:  Jay A Lieberman; Mirna Chehade
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

Review 8.  Immunology and clinical manifestations of non-clonal mast cell activation syndrome.

Authors:  Juan-Carlos Cardet; Mariana C Castells; Matthew J Hamilton
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

9.  Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab.

Authors:  Sofie Lieberoth; Simon Francis Thomsen
Journal:  Case Rep Med       Date:  2015-01-28

10.  Omalizumab, an anti-immunoglobulin E antibody: state of the art.

Authors:  Cristoforo Incorvaia; Marina Mauro; Marina Russello; Chiara Formigoni; Gian Galeazzo Riario-Sforza; Erminia Ridolo
Journal:  Drug Des Devel Ther       Date:  2014-02-07       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.